Clinical Trials
39 trialsOblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University of Nebraska
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
National Cancer Institute (NCI)
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
M.D. Anderson Cancer Center
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
National Cancer Institute (NCI)
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301
National Cancer Institute (NCI)
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Oblimersen in Treating Patients With Merkel Cell Carcinoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
Genta Incorporated
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Genta Incorporated
AGENDA
Genta Incorporated
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Genta Incorporated
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)
Genta Incorporated
A Phase I Study of G3139 Subcutaneous in Solid Tumors
Genta Incorporated